医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Company Profile for Laurus Labs Limited

2017年05月19日 PM12:40
このエントリーをはてなブックマークに追加


 

Laurus is a leading research and development driven pharmaceutical company in India. The Company has grown consistently to become one of the leading manufacturers of Active Pharmaceutical Ingredients (APIs) for anti-retroviral (ARV) and Hepatitis C. Laurus also manufactures APIs in Oncology and other therapeutic areas. Its strategic and early investments in R&D and manufacturing infrastructure have enabled it to become one of the leading suppliers of APIs in the ARV therapeutic area. Initiatives are in place to develop a Finished Dosage Forms capabilities on the back of existing strengths in APIs. The Company is also driving growth opportunities in the Synthesis and Ingredients businesses.

 

Company:

  Laurus Labs Limited
 

Headquarters Address:

2nd Floor Serene Towers, Rd No 5, Banjarahills,
Hyderabad 500034
India
 

Main Telephone:

+91 40 3980 4333
 

Website:

www.lauruslabs.com

 

Ticker/ISIN:

540222(MUMBAI)/INE947Q01010

LAURUSLABS(NSI)/INE947Q01010

 

Type of Organization:

Public
 

Industry:

Pharmaceutical
 

Earnings Release Dates:

4th Quarter: May 18, 2017

 

Key Executives:

CEO: Satyanarayana Chava

CFO: V V Ravi Kumar

 

Public Relations

Contact:

Pavan Kumar

Phone:

+91 40 3980 4380

Email:

pavankumar.n@lauruslabs.com

View source version on businesswire.com: http://www.businesswire.com/news/home/20170518005424/en/

CONTACT

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Groundbreaking Multi-Center Clinical Trial Confirms Low-Dose Aspirin Therapy Reduces Rate of Pre-Term Preeclampsia
  • 武田薬品、初発多発性骨髄腫患者および維持療法でニンラーロ(イキサゾミブ)を検討する第1/2相試験のデータを発表
  • LEDを自然な光に回帰させるソウル半導体の新技術“SunLike”
  • 武田呈报NINLARO™ (ixazomib)用于新诊断多发性骨髓瘤患者及维持治疗的1/2期研究数据
  • Eloxx Pharmaceuticals Receives a US$6 Million Investment from KIP and DCS to Advance a Novel Disease-Modifying Therapy Targeting Genetic Diseases Including Cystic Fibrosis